Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 6/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4374730 | 1.00 | KMT2A (0.40) | KMT2APTGER4HRH3TSHRHRH1 | |
| SCHEMBL4375203 | 0.88 | PTGER4 (0.38) | KMT2APTGER4TSHRPTGER3PTGER2 | |
| SCHEMBL4375210 | 0.88 | PTGER4 (0.38) | KMT2APTGER4TSHRPTGER3PTGER2 | |
| SCHEMBL5766710 | 0.87 | PTGER4 (0.37) | KMT2APTGER4TSHRPTGER3PTGER2 | |
| SCHEMBL4683709 | 0.84 | PTGER4 (0.45) | KMT2APTGER4HRH3TSHRHRH1 | |
| SCHEMBL4383134 | 0.84 | PTGER4 (0.45) | KMT2APTGER4HRH3TSHRHRH1 | |
| SCHEMBL1074993 | 0.81 | PTGER4 (0.41) | KMT2APTGER4PTGER3PTGER2ALDH1A1 | |
| SCHEMBL1074995 | 0.81 | PTGER4 (0.41) | KMT2APTGER4PTGER3PTGER2ALDH1A1 | |
| SCHEMBL4389223 | 0.80 | KMT2A (0.38) | KMT2AHRH3TSHRALDH1A1CYP2D6 | |
| SCHEMBL4389232 | 0.80 | KMT2A (0.38) | KMT2AHRH3TSHRALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631355-B1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | ALLERGAN INC (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-1817033-B1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALLERGAN INC (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-1722795-B1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | ALLERGAN INC (US) | 2008-05-07 | — | — | EP | disclosed |
| US-7326716-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1817033-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | Allergan, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| US-7179820-B2 | Piperidinyl prostaglandin E analogs | ALLERGAN, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| WO-2006058080-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALLERGAN, INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| US-6977260-B2 | administering to an animal having ocular hypertension a piperidynly analog; a container adapted to dispense the ophthalmic solution in a metered form | ALLERGAN, INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050171062-A1 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050164990-A1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | ALLERGAN, INC. | 2005-07-28 | — | — | US | disclosed |
| US-20040248854-A1 | Piperidinyl prostaglandin E analogs | ALLERGAN, INC. | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164990-A1 | PIPERIDINYL PROSTAGLANDIN E ANALOGS | PTGIR, PTGDR, PTGER1 | KMT2A 4036/4885PTGER4 12/4885HRH3 731/4885 |
| US-20050171062-A1 | Treatment of inflammatory bowel disease | SLC10A2, GUCY1B1, PTGER1 | KMT2A 4220/4885PTGER4 18/4885HRH3 770/4885 |
| US-20040248854-A1 | Piperidinyl prostaglandin E analogs | PTGIR, PTGER1, PTGS1 | KMT2A 4030/4885PTGER4 14/4885HRH3 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.